What Algifor Dolo Junior treats: main uses and benefits

The therapeutic role of Algifor Dolo Junior is focused on providing short-term symptomatic assistance across the core domains of pain, fever, and inflammation. The medicine is relevant in contexts involving elevated physiological stress and discomfort.

Symptomatic Support for Acute Episodes

This formulation is used to address distressing symptoms, primarily by reducing elevated body temperature (fever). It is commonly used during acute episodes, such as those associated with the common cold and flu, where supportive symptom management is appropriate. The medicine also assists with managing painful manifestations like headache, toothache, earache (otitis media), and discomfort from teething. This supportive relief helps patients manage symptom fluctuations and assists in maintaining functional stability when symptoms interfere with routine activities.

It is also applied in addressing symptoms related to inflammatory or irritative states, such as localized swelling following minor sprains or injuries, and for chronic conditions characterized by periods of heightened symptoms, such as juvenile arthritis.

---

Quick Fact: Relief for Pain, Fever, and Inflammation This action is used to help with symptoms related to physical discomfort, supporting a reduction in the overall symptom burden across these three key categories.

Eligibility Map: Who can and cannot use Algifor Dolo Junior — Official Regulatory Information

---

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Pediatric patient group (children and adolescents).
• Infants aged 3 months and older and weighing mathbfge 5 kg.
• Lactating women (considered compatible).

Populations for whom use is not recommended (if applicable):

• Pregnant individuals after week 20 of gestation.
• Children and adolescents who are dehydrated (due to risk of renal impairment).
• Women attempting to conceive.

Populations for whom use is contraindicated:

• Patients with known hypersensitivity to Ibuprofen, other NSAIDs, or Aspirin.
• Patients with active or recurrent gastrointestinal haemorrhage or ulceration.
• Patients with severe hepatic, renal, or heart failure (NYHA Class IV).
• Pregnant individuals during the third trimester.

---

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents):

• Contraindicated: Absolute prohibition (e.g., severe organ failure, NSAID allergy).
• Use Not Recommended/Restricted: Conditional use requiring special consideration (e.g., mild-to-moderate organ impairment, dehydration).

Regulatory basis (EMA / FDA / etc.):

• Restrictions are based on the Ibuprofen core drug profile and its classification as an NSAID.

Eligibility-context constraints (as defined in official documents):

• Restrictions are defined by pre-existing disease states (e.g., GI ulcer) and physiological states (e.g., pregnancy).

---

Resulting eligibility structure

Official eligibility statements:

• Use is contraindicated in patients with a history of NSAID-induced hypersensitivity or active GI bleeding.
• The medicine is contraindicated during the third trimester of pregnancy.
• Use requires caution in patients with mild-to-moderate organ impairment or a history of chronic GI disease.

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents define the eligibility profile by clearly segmenting populations into permitted, restricted-use, and contraindicated categories. This structure is governed by the inherent risks of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), linking pre-existing conditions—such as severe organ dysfunction and active gastrointestinal disease—to formal exclusion. The label sets explicit boundaries for use concerning age, requiring a minimum threshold for infants and special caution for the elderly, reflecting standardized regulatory guidance.

The official interaction profile for the active ingredient, Ibuprofen, is structured around documented pharmacokinetic and pharmacodynamic constraints defined in government labeling.

Restrictions on Co-administration

Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, is restricted due to an additive risk of severe adverse gastrointestinal effects. Pharmacodynamic interactions with Anticoagulants (such as Warfarin), Corticosteroids, and Selective Serotonin Reuptake Inhibitors (SSRIs) also increase the officially recognized risk of gastrointestinal bleeding or ulceration. Additionally, concomitant use with alcohol is documented to increase the risk of active substance-related adverse effects, particularly those concerning the gastrointestinal tract.

Exposure and Efficacy Modification

Ibuprofen is officially documented to reduce the renal clearance of substances such as Lithium and Methotrexate. This pharmacokinetic effect can lead to increased plasma concentrations of these medicines. Furthermore, Ibuprofen can diminish the antihypertensive effect of ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs), and diuretics, reducing their expected efficacy.

Timing and Population Notes

A mandatory timing separation is required when co-administering Ibuprofen with low-dose Acetylsalicylic Acid (Aspirin) taken for its antiplatelet effect. When co-administered with ACE Inhibitors or ARBs, the potential risk of deteriorating renal function is noted as being particularly relevant in elderly and volume-depleted patients.

How Algifor Dolo Junior Works

The mechanism of action for Algifor Dolo Junior is defined by the pharmacodynamic activity of its active ingredient, Ibuprofen, operating across three distinct biological domains to interfere with prostaglandin-mediated signaling.

Modulation of Prostanoid Synthesis

This domain covers the drug’s primary action: the reversible inhibition of the Cyclooxygenase ( COX) enzymes ( COX-1 and COX-2). By binding to the active site, Ibuprofen blocks the conversion of arachidonic acid into chemical signaling molecules called prostanoids ( PGE2 and PGI2). This suppression modifies early molecular steps that shape systemic physiological outcomes by reducing the biosynthesis of key mediators involved in tissue-level signaling.

Resetting the Central Thermoregulatory Set Point

This mechanism occurs in the Central Nervous System (CNS), specifically within the hypothalamus. The reduction of PGE2 synthesis in this area adjusts the elevated thermoregulatory set point caused by pyrogenic substances. This adjustment initiates a physiological cascade, promoting heat dissipation (e.g., peripheral vasodilation), which is the consequence of resetting the thermoregulatory set point within targeted central pathways.

Controlling Peripheral Nociceptor Sensitization

At peripheral sites, the mechanism interferes with the process by which locally synthesized prostaglandins sensitize peripheral nociceptors (pain-sensing nerve endings). By maintaining a higher activation threshold for these nerves, the mechanism limits the impact of excessive mediator activity and results in a reduction of peripheral sensory response amplitude.

The administration of Ibuprofen oral suspension, a medicine designated for the pediatric patient group, is governed by standardized protocols to ensure proper procedural use. The drug is approved exclusively for the oral route of administration.

Administration Scope

Property	Instruction
Route of administration	The product is approved for the oral route of administration.
Dosing schedule	Dosing is standardized on a weight-based regimen, calculated at 5 to 10 mg of Ibuprofen per kg of body weight.
Timing in relation to meals	The dose may be administered with food or milk if the patient experiences gastric discomfort.
Preparation requirements	The oral suspension bottle must be shaken well immediately prior to measuring and administration.
Age-group administration rules	Administration to infants under six months of age is subject to a mandatory medical consultation for dose determination.
Special procedural conditions	The dose must be measured precisely in milliliters (mL) using only the measuring device provided with the product.

---

Instruction Classifications

Property	Classification
Frequency pattern	As-needed basis, repeating every 6 to 8 hours with a maximum of four doses in 24 hours.
Use-context constraints	Usage is limited to short-term symptomatic management, generally not exceeding three days without professional medical advice.

---

Resulting Procedural Structure

Official instructions establish a precise, weight-dependent oral dosing model to standardize the amount of medicine based on the patient’s physiological metrics. This administration is then constrained by a clear time-based regimen, which mandates a minimum 6 to 8 hour interval between doses and strictly limits the total number of administrations in any 24-hour period. These protocols, including the requirement to use the provided measuring tool and to shake the suspension bottle, define the standardized approach for the reliable delivery of the dose.

Recent Clinical Evidence

This section describes the major clinical studies that evaluated the active substance in Algifor Dolo Junior for the management of pain and fever in children.

Core Efficacy and Safety Research

Studies of the active substance are commonly conducted as randomized, controlled trials (RCTs). The primary aim of this research often involves examining whether the substance affects fever resolution (antipyresis) and pain levels (analgesia) across specific time points, compared to a placebo or other active treatments, such as paracetamol.

• Fever Management: Research consistently demonstrates that the active substance is associated with measurable reductions in body temperature. Comparative studies have often assessed whether the drug affects the rate of fever resolution or the duration of its effect, particularly in children under two years old.
• Pain Relief: Studies have evaluated the substance's effect on various types of mild-to-moderate pain, including that associated with colds, flu, and common musculoskeletal injuries. Measured endpoints included changes in functional mobility scores or subjective pain ratings reported by participants.

Comparative Effectiveness

Clinical trials have explored the relative outcomes of the active substance versus other common analgesics/antipyretics in the pediatric population. These studies primarily focused on two areas:

Research Focus	Study Endpoint Assessment
Monotherapy Comparison	Assessment of temperature reduction over a defined period (e.g., 6 hours). Results have described similar or variable outcomes compared to paracetamol.
Combination Use	Evaluation of giving the drug with paracetamol versus monotherapy. Research assessed differences in time to symptom reduction and the overall incidence of adverse events.

Subpopulation Studies and Limitations

Research has explored the drug's impact across specific patient groups, such as children with co-existing conditions. Evidence remains limited from studies assessing patients with severe underlying autoimmune or gastrointestinal disorders. Ongoing research continues to examine the relationship between the drug's administration and the promptness or sustained nature of the measured variables.

Important Note

This summary is strictly based on research findings and is for informational purposes only. Information about this treatment option is available to discuss with a healthcare professional. It does not offer medical advice, diagnostic services, or recommendations for treatment.

Key Studies & References

1. NICE Guideline NG160: Fever in under 5s: assessment and initial management

Common questions about Algifor Dolo Junior (FAQ)

Q: Can I drink alcohol while taking this medicine?

Official product information notes that drinking alcohol while taking this medicine may increase the risk of central nervous system side effects. These effects may include drowsiness and impaired awareness or concentration.

Q: What are the storage conditions for this medicine?

According to regulatory documents, this medicine should be stored below 30 C. It is also important to protect the medication from light and moisture to help maintain the medicine’s quality.

Q: What are the contraindications (who should not take it)?

Regulatory information states that this medicine is contraindicated, meaning it should not be taken, if you are hypersensitive. Hypersensitivity means you have had an allergic reaction to the active substance, pregabalin, or any of the other ingredients used in the formulation.

Q: What is the advice for pregnancy?

Official product labeling indicates that this medicine may cause fetal harm and has been associated with major birth defects when used during the first trimester of pregnancy. Official guidance recommends that women of childbearing potential use effective contraception throughout treatment.

Q: What is the advice for breastfeeding?

Based on regulatory information, breastfeeding is not recommended while undergoing treatment. This is due to the drug passing into human milk and the potential risks that were observed in some high-dose animal studies.

Q: Does this medicine cause drowsiness or make you sleepy?

Yes, dizziness and somnolence (sleepiness) are two of the very common adverse reactions listed in the official safety information. Patients are advised to be aware of these potential effects, particularly when first starting treatment.

Q: Does it have a risk of addiction or dependence?

Official safety information includes warnings about the potential risks of abuse, misuse, and physical dependence associated with this medicine. Physical dependence means your body may become used to the drug, which may lead to withdrawal symptoms if it is stopped suddenly.

Q: Can children 2 years old use it?

Regulatory documents indicate there is not enough data or information to recommend the use of this medicine in children under the age of 18 years.

Official Storage and Disposal Instructions

Storage and disposal protocols for this ibuprofen oral suspension are strictly defined in regulatory documents to ensure product stability and public safety.

Mandatory Storage Conditions

Requirement	Classification
Temperature	Controlled Room Temperature: 15^circmathrmC to 30^circmathrmC (59^circmathrmF to 86^circmathrmF)
Container	Store in the original container with the cap tightly closed.
Child Safety	Keep out of the sight and reach of children.

Disposal Requirements

Official instructions mandate that the best disposal method for unused or expired medicine is an authorized drug take-back program. The product must not be flushed down the toilet or poured into the sink, as it is not designated for wastewater disposal. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance, sealed in a bag or container, and placed in the household trash, in accordance with local regulations.